Head to Head Survey: Lipella Pharmaceuticals (LIPO) and The Competition

Lipella Pharmaceuticals (NASDAQ:LIPO) is one of 1,049 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Lipella Pharmaceuticals to similar businesses based on the strength of its risk, profitability, analyst recommendations, institutional ownership, valuation, dividends and earnings.

Profitability

This table compares Lipella Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lipella Pharmaceuticals	-882.82%	-192.33%	-154.24%
Lipella Pharmaceuticals Competitors	-3,610.16%	-274.38%	-39.07%

Analyst Recommendations

This is a summary of recent ratings and price targets for Lipella Pharmaceuticals and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipella Pharmaceuticals	0	0	1	0	3.00
Lipella Pharmaceuticals Competitors	7622	20910	48555	1193	2.55

Lipella Pharmaceuticals presently has a consensus price target of $16.00, suggesting a potential upside of 471.43%. As a group, “Pharmaceutical preparations” companies have a potential upside of 71.08%. Given Lipella Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe Lipella Pharmaceuticals is more favorable than its competitors.

Volatility and Risk

Lipella Pharmaceuticals has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500. Comparatively, Lipella Pharmaceuticals’ competitors have a beta of 1.05, meaning that their average stock price is 5% more volatile than the S&P 500.

Valuation & Earnings

This table compares Lipella Pharmaceuticals and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Lipella Pharmaceuticals	$483,533.00	-$4.62 million	-0.66
Lipella Pharmaceuticals Competitors	$1.72 billion	$154.00 million	-5.60

Lipella Pharmaceuticals’ competitors have higher revenue and earnings than Lipella Pharmaceuticals. Lipella Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by company insiders. Comparatively, 13.8% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Lipella Pharmaceuticals beats its competitors on 8 of the 13 factors compared.

About Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.